Divi's Laboratories liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

49.81×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
5.43×	5.43×	6.94×	7.57×	8.46×
3.50×	3.50×	4.71×	5.08×	5.73×
128	128	415	363	170
9,053	9,053	8,629	8,397	8,211

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DIVISLAB₹9,664.00

Divi's Laboratories Ltd.

· Pharma & Health

₹ CrorePeersLAURUSLABS COHANCE GLAND TORNTPHARM ZYDUSLIFE MAXHEALTH DRREDDY CIPLAMcap ₹2.56L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	49.81
Current Ratio	8.46	7.57	6.94	5.43	5.43
Quick Ratio	5.73	5.08	4.71	3.50	3.50
Cash, Equiv & ST Investments	169.7	363.0	415.0	128.0	128.0
Working Capital	8,210.7	8,397.0	8,629.0	9,053.0	9,053.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.